SS Innovations International, Inc. $SSII

What the company doesAI summary of filing

SS Innovations International, Inc. designs, manufactures, and markets the SSi Mantra, a surgical robotic system intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic, and cardiac surgeries. The company is revenue-generating, having received regulatory approval from India's CDSCO in late 2022 and commercially launched the SSi Mantra in India, where it has installed 168 systems as of December 31, 2025, which have been used to perform more than 7,800 surgical procedures across 153 hospitals. The company generates revenue from the sale of the SSi Mantra through three models: outright purchase, deferred or installment payment, and pay-per-procedure basis, and also earns recurring revenue from the sales of instruments, accessories, and services. The company is pursuing regulatory approvals in the U.S. and EU, having submitted a 510(k) premarket notification to the FDA in December 2025 and technical files to an EU Notified Body, with stated expectations to secure approvals in 2026, though there is no assurance as to timing or outcome. [10-K 2026-03-10]

Segments: SSi Mantra Surgical Robotic System, SSi Mudra Instruments and Accessories, Telesurgery and Tele-Proctoring Services, SSi Maya Digital Platform